Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4)

Ziyan Yuan Pessetto, Ying Yan, Tadayoshi Bessho, Amarnath Natarajan

Research output: Contribution to journal › Comment/debate

Original languageEnglish (US)
Number of pages1
JournalBreast Cancer Research and Treatment
Volume155
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Phosphoproteins
Breast Neoplasms
Therapeutics
olaparib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Erratum to : Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4). / Pessetto, Ziyan Yuan; Yan, Ying; Bessho, Tadayoshi; Natarajan, Amarnath.

In: Breast Cancer Research and Treatment, Vol. 155, No. 3, 01.02.2016.

Research output: Contribution to journal › Comment/debate

Pessetto, ZY, Yan, Y, Bessho, T & Natarajan, A 2016, 'Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4)', Breast Cancer Research and Treatment, vol. 155, no. 3. https://doi.org/10.1007/s10549-016-3702-6
Pessetto ZY, Yan Y, Bessho T, Natarajan A. Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4). Breast Cancer Research and Treatment. 2016 Feb 1;155(3). https://doi.org/10.1007/s10549-016-3702-6
Pessetto, Ziyan Yuan ; Yan, Ying ; Bessho, Tadayoshi ; Natarajan, Amarnath. / Erratum to : Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4). In: Breast Cancer Research and Treatment. 2016 ; Vol. 155, No. 3.
@article{438af67081b7449db41e722fdd48c652,
title = "Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4)",
author = "Pessetto, {Ziyan Yuan} and Ying Yan and Tadayoshi Bessho and Amarnath Natarajan",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s10549-016-3702-6",
language = "English (US)",
volume = "155",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Erratum to

T2 - Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option (Breast Cancer Res Treat, (2012) 134, 511–517, 10.1007/s10549-012-2079-4)

AU - Pessetto, Ziyan Yuan

AU - Yan, Ying

AU - Bessho, Tadayoshi

AU - Natarajan, Amarnath

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://www.scopus.com/inward/record.url?scp=84959116168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959116168&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3702-6

DO - 10.1007/s10549-016-3702-6

M3 - Comment/debate

C2 - 26883325

AN - SCOPUS:84959116168

VL - 155

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -

Access to Document